| Dr Sarah L Brewer, DO | |
|
315 S Osteopathy St, Kirksville, MO 63501 | |
| (660) 785-1000 | |
| Not Available |
| Full Name | Dr Sarah L Brewer |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 22 Years |
| Location | 315 S Osteopathy St, Kirksville, Missouri |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1902829963 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Davis County Hospital | Bloomfield, IA | Hospital |
| Northeast Regional Medical Center | Kirksville, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Davis County Hospital | 3971493040 | 10 |
News Archive
Keryx Biopharmaceuticals, Inc. today announced that abstract O-0017, entitled "Subset Analysis of 5-FU Refractory Patients from a Randomized Ph II Study of Perifosine + Capecitabine (P-CAP) vs. Placebo + Capecitabine (CAP) in Patients with 2nd or 3rd Line Metastatic CRC" has been selected for oral presentation at the upcoming 12th World Congress on Gastrointestinal Cancer, to be held in Barcelona, Spain from June 30 - July 2, 2010.
Pregnant and breastfeeding women have been excluded from clinical trials of drugs to treat COVID-19, and as result, there is no safety data to inform clinical decisions. Such drugs include remdesivir according to a new article in the peer-reviewed journal Breastfeeding Medicine.
It's unclear whether all patients with advanced rectal cancer need chemoradiotherapy, or whether some can forego the treatment and therefore be spared its side effects.
Entos Pharmaceuticals Inc. ("Entos" or the "Company"), a healthcare biotechnology company focused on the development of next-generation nucleic acid-based therapies using their Fusogenix drug delivery platform, today announced it has entered into a research, development and collaboration agreement ("Agreement") with a clinical stage biopharmaceutical company ("Partner") focused on the development of novel therapeutic compounds targeting autoimmune and inflammatory diseases.
With the start of summer comes the appearance of common stinging insects, such as bees, wasps, hornets and yellowjackets, and the various related health risks that range from irritating but relatively harmless stings to the threat of serious allergic reaction. The National Pest Management Association (NPMA) stresses that when it comes to stinging insects, the best way to avoid the associated health risks is to practice simple prevention and treatment tips.
› Verified 4 days ago
| Entity Name | Davis County Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487740486 PECOS PAC ID: 3971493040 Enrollment ID: O20040319001367 |
News Archive
Keryx Biopharmaceuticals, Inc. today announced that abstract O-0017, entitled "Subset Analysis of 5-FU Refractory Patients from a Randomized Ph II Study of Perifosine + Capecitabine (P-CAP) vs. Placebo + Capecitabine (CAP) in Patients with 2nd or 3rd Line Metastatic CRC" has been selected for oral presentation at the upcoming 12th World Congress on Gastrointestinal Cancer, to be held in Barcelona, Spain from June 30 - July 2, 2010.
Pregnant and breastfeeding women have been excluded from clinical trials of drugs to treat COVID-19, and as result, there is no safety data to inform clinical decisions. Such drugs include remdesivir according to a new article in the peer-reviewed journal Breastfeeding Medicine.
It's unclear whether all patients with advanced rectal cancer need chemoradiotherapy, or whether some can forego the treatment and therefore be spared its side effects.
Entos Pharmaceuticals Inc. ("Entos" or the "Company"), a healthcare biotechnology company focused on the development of next-generation nucleic acid-based therapies using their Fusogenix drug delivery platform, today announced it has entered into a research, development and collaboration agreement ("Agreement") with a clinical stage biopharmaceutical company ("Partner") focused on the development of novel therapeutic compounds targeting autoimmune and inflammatory diseases.
With the start of summer comes the appearance of common stinging insects, such as bees, wasps, hornets and yellowjackets, and the various related health risks that range from irritating but relatively harmless stings to the threat of serious allergic reaction. The National Pest Management Association (NPMA) stresses that when it comes to stinging insects, the best way to avoid the associated health risks is to practice simple prevention and treatment tips.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sarah L Brewer, DO 1604 E Washington St, Kirksville, MO 63501-3362 Ph: (660) 341-8533 | Dr Sarah L Brewer, DO 315 S Osteopathy St, Kirksville, MO 63501 Ph: (660) 785-1000 |
News Archive
Keryx Biopharmaceuticals, Inc. today announced that abstract O-0017, entitled "Subset Analysis of 5-FU Refractory Patients from a Randomized Ph II Study of Perifosine + Capecitabine (P-CAP) vs. Placebo + Capecitabine (CAP) in Patients with 2nd or 3rd Line Metastatic CRC" has been selected for oral presentation at the upcoming 12th World Congress on Gastrointestinal Cancer, to be held in Barcelona, Spain from June 30 - July 2, 2010.
Pregnant and breastfeeding women have been excluded from clinical trials of drugs to treat COVID-19, and as result, there is no safety data to inform clinical decisions. Such drugs include remdesivir according to a new article in the peer-reviewed journal Breastfeeding Medicine.
It's unclear whether all patients with advanced rectal cancer need chemoradiotherapy, or whether some can forego the treatment and therefore be spared its side effects.
Entos Pharmaceuticals Inc. ("Entos" or the "Company"), a healthcare biotechnology company focused on the development of next-generation nucleic acid-based therapies using their Fusogenix drug delivery platform, today announced it has entered into a research, development and collaboration agreement ("Agreement") with a clinical stage biopharmaceutical company ("Partner") focused on the development of novel therapeutic compounds targeting autoimmune and inflammatory diseases.
With the start of summer comes the appearance of common stinging insects, such as bees, wasps, hornets and yellowjackets, and the various related health risks that range from irritating but relatively harmless stings to the threat of serious allergic reaction. The National Pest Management Association (NPMA) stresses that when it comes to stinging insects, the best way to avoid the associated health risks is to practice simple prevention and treatment tips.
› Verified 4 days ago
Dr. Azhar Assadi, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 315 S Osteopathy Ave, Kirksville, MO 63501 Phone: 660-785-1000 | |
Dr. Maura Beth Gerdes, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1605 S. Baltimore St., Suite B, Kirksville, MO 63501 Phone: 660-665-3599 Fax: 660-665-7576 | |
David Vincent Spencer, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1605 S Baltimore St Ste B, Kirksville, MO 63501 Phone: 660-627-3363 Fax: 660-627-3367 | |
Cameron Sinclair Olsen, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 315 S Osteopathy Ave, Kirksville, MO 63501 Phone: 801-234-9790 | |
Dr. Stephen James Hyde, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 315 S Osteopathy Ave, Kirksville, MO 63501 Phone: 660-785-1000 | |
Valena Fiscus, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 800 W Jefferson St, Kirksville, MO 63501 Phone: 660-626-2223 | |
Larry R Handlin, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 800 W Jefferson St, Kirksville, MO 63501 Phone: 660-785-1991 Fax: 660-785-1989 |